FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	en							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Singh Shawn				2. Issuer Name and Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VTGN]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 04/26/2017							CHIEF EXECUTIVE OFFICE				pecify
(Street) SOUTH SAN FRANCISCO CA 94080				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(S	tate)	(Zip)													
		Та	ble I - Non-	Derivati	ve Se	ecurities	s Ac	quired, D	isposed (of, or Be	neficially	/ Owned				
Date			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea		e, Transaction Dispo Code (Instr.		eurities Acquired (A) o sed Of (D) (Instr. 3, 4		Beneficia Owned Fe	s Fally (I	Form:	Direct III	7. Nature of Indirect Beneficial Ownership	
								Code	Amount	(A) (D)	Price	Transacti	Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
			Table II - De					uired, Dis , options				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Execution (Month/Day/Year) if any	3A. Deemed Execution Date if any (Month/Day/Yea	Date, Transacti Code (Ins				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s (Instr. 4)			
Stock Option (Right to Buy)	\$1.96	04/26/2017		A		175,000		(1)	04/26/2027	Common Stock	175,000	\$0	175,00	00	D	

Explanation of Responses:

1. One third (1/3rd) of the total shares shall vest one (1) year following the date of grant and 1/24th of the remaining number of shares shall vest monthly thereafter until all awarded shares are fully vested three (3) years from the date of grant.

/s/ Jerrold D. Dotson, Attorney- 04/28/2017

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.